Allergy Therapeutics at H.C. Wainwright Conference

RNS Number : 3467M

Allergy Therapeutics PLC

23 May 2022

 

Allergy Therapeutics plc

(" A l l e r gy   T he r a peu t i cs", the "Group"   or   " C o m p a n y " )

Allergy Therapeutics to Present at the H.C. Wainwright Global Investment Conference

23 May 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that company management will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

The virtual presentation will be available to registered attendees of the conference for on-demand viewing beginning May 24, 2022 at 7:00 a.m. ET/12:00 p.m. BST. A replay of the presentation will be made available under the 'Investors' section on Allergy Therapeutics' website at  www.allergytherapeutics.com/investors/results-reports-and-presentations/ .

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see  www.allergytherapeutics.com .

 

END

 

 

NRAATMRTMTITBBT